Teduglutide is the kind of peptide drug that doesn't make headlines — but for the few thousand people in the United States living with short bowel syndrome and chronic intestinal failure, it has been life-changing. By engineering a single amino acid swap into the gut-protective hormone GLP-2, scientists turned a peptide with a 7-minute half-life into a daily injection that grows the intestinal lining, increases nutrient absorption, and lets patients spend less time tethered to total parenteral nutrition (TPN) bags.
This deep dive covers the GLP-2 biology, the alanine-2 substitution that made the drug possible, the STEPS trial that earned FDA approval in 2012, the orphan-drug pricing controversy, and the next generation of long-acting GLP-2 analogs now in late-stage development.
What Is Teduglutide?
Teduglutide (originally ALX-0600, then marketed as Gattex in the U.S. and Revestive in Europe) is a 33-amino-acid recombinant analog of human glucagon-like peptide-2 (GLP-2). GLP-2 is co-secreted with GLP-1 from intestinal L-cells in response to nutrient ingestion. While GLP-1 became famous as the parent of Ozempic and Wegovy, GLP-2 acts almost exclusively on the gut itself: it expands enterocyte mass, lengthens villi, reduces intestinal permeability, and improves nutrient absorption.
The problem is that native GLP-2 is destroyed almost immediately by dipeptidyl peptidase-4 (DPP-4), the same enzyme that inactivates GLP-1. Native GLP-2 has a circulating half-life of about 7 minutes — useless as a drug. Teduglutide solves this with a single amino acid change: alanine at position 2 is replaced with glycine, which removes the DPP-4 cleavage site. The half-life jumps to roughly 2 hours, more than long enough for once-daily subcutaneous dosing.
Approval timeline
- 2000s — NPS Pharmaceuticals develops ALX-0600 from earlier GLP-2 work by Daniel Drucker (University of Toronto) and colleagues.
- 2012 — FDA approves teduglutide (Gattex) for adults with short bowel syndrome dependent on parenteral support. NPS is acquired by Shire in 2015; Shire is acquired by Takeda in 2019.
- 2019 — FDA approves teduglutide for pediatric patients ≥1 year old with SBS-IF.
- 2023 — Label expansion includes additional pediatric data; Takeda continues post-marketing follow-up.
- Ongoing — Zealand Pharma's glepaglutide and VectivBio's apraglutide (now part of Ironwood) are advancing as longer-acting next-generation GLP-2 analogs.
Mechanism of Action
Teduglutide is a selective agonist at the GLP-2 receptor (GLP-2R), a class B GPCR expressed primarily on enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons of the small intestine. GLP-2R activation does not act directly on enterocytes; instead it triggers paracrine release of mediators including insulin-like growth factor 1 (IGF-1), keratinocyte growth factor (KGF), and ErbB ligands that drive crypt cell proliferation.
The downstream effects on gut physiology include:
- Villous height and crypt depth increase, expanding absorptive surface area.
- Intestinal blood flow increases, supporting nutrient transport.
- Tight junction integrity improves, reducing intestinal permeability.
- Gastric emptying slows modestly, increasing nutrient contact time.
- Bowel motility decreases, again improving absorption.
The net clinical effect: more calories, fluids, and electrolytes absorbed enterally, and less need for IV nutrition.
Pivotal Clinical Trials
Jeppesen et al., 2012 — STEPS Trial (Gastroenterology)
The STEPS trial (Study of Teduglutide in PN-Dependent Short Bowel Syndrome) was the registrational study. 86 adults with SBS dependent on parenteral support for at least 12 months were randomized to teduglutide 0.05 mg/kg/day SC or placebo for 24 weeks.
Primary endpoint: ≥20% reduction in weekly parenteral support volume at weeks 20 and 24.
- 63% of teduglutide patients met the primary endpoint vs. 30% on placebo (p = 0.002).
- Mean reduction in PN volume was 4.4 L/week with teduglutide vs. 2.3 L/week with placebo.
- 21 of 39 teduglutide patients achieved at least one full day per week off parenteral support, vs. 9 of 43 on placebo.
Schwartz et al., 2016 — STEPS-2 Extension (Clinical and Translational Gastroenterology)
The 2-year open-label extension showed that benefits accrued over time: 93% of patients achieved a ≥20% reduction in PN, and 13 patients achieved complete enteral autonomy (came off parenteral nutrition entirely).
Carter et al., 2017 — Pediatric Trial (Journal of Pediatric Surgery)
A 24-week pediatric trial in 59 children with SBS-IF showed similar response rates and supported the 2019 pediatric label expansion. Three patients weaned completely off PN.
Approved Indications & Use
Teduglutide is FDA-approved for:
- Adults and pediatric patients ≥1 year of age with short bowel syndrome who are dependent on parenteral support.
It is given as a daily subcutaneous injection (0.05 mg/kg/day) into the thigh, abdomen, or upper arm. Treatment is typically open-ended; benefits accrue over months and reverse if the drug is stopped.
Clinical workflow involves close collaboration between gastroenterologists, dietitians, and home parenteral nutrition teams. Baseline colonoscopy is required (and repeated periodically) because of theoretical concerns about accelerated growth of intestinal polyps and neoplasia.
The cost has been controversial. Gattex carries an average wholesale price of roughly $295,000–$400,000 per year, reflecting orphan drug pricing for an ultra-rare indication. Insurance battles, prior authorizations, and patient assistance programs are routine parts of the treatment journey.
Side Effects & Safety
Common adverse effects largely reflect the trophic action of GLP-2 on the gut and surrounding structures:
- Abdominal pain, nausea, abdominal distension — typical and dose-related
- Injection-site reactions — common but usually mild
- Stoma complications in patients with ileostomies (swelling, increased output)
- Fluid overload and peripheral edema
- Headache, upper respiratory tract infection
- Cholecystitis, cholelithiasis, biliary obstruction — GLP-2 effects on gallbladder
- Pancreatitis — uncommon but reported
Notable warnings
- Acceleration of neoplastic growth — because teduglutide drives epithelial proliferation, the label warns about potential for accelerating polyp or cancer growth. Colonoscopy is mandated before starting therapy and at regular intervals during treatment.
- Intestinal obstruction — the trophic effect can occasionally cause stenosis or obstruction in patients with strictures.
- Volume overload — improved absorption can unmask cardiovascular issues in patients chronically dependent on managed IV fluids.
Connection to Gene Editing & Modern Peptide Therapy
The GLP-1 / GLP-2 / glucagon family is a master class in how a single peptide gene (proglucagon) yields multiple hormones with specialized roles, and how clever peptide engineering can lock each one in for therapeutic use. Teduglutide and the GLP-1 agonists share a parent gene, a common DPP-4 vulnerability, and a common engineering trick (block position 2 cleavage). For more on how this family is being mined for new drugs, see how GLP-1 drugs work and our semaglutide and tirzepatide deep dive.
Looking ahead, glepaglutide (Zealand Pharma) and apraglutide (Ironwood) are next-generation GLP-2 analogs designed for less frequent dosing — twice-weekly to weekly — using albumin-binding strategies similar to those that gave us once-weekly semaglutide. And researchers are exploring whether AAV-delivered gene therapy could provide endogenous GLP-2 production for patients with severe SBS, an approach related to longer-term thinking about base editing as an alternative to chronic peptide injections.
FAQ
What is short bowel syndrome?
SBS is a malabsorption disorder caused by surgical loss or congenital absence of large segments of the small intestine. Causes include Crohn's disease, mesenteric ischemia, volvulus, trauma, and necrotizing enterocolitis. Severely affected patients require total parenteral nutrition.
How does teduglutide differ from native GLP-2?
A single substitution — alanine 2 to glycine — blocks DPP-4 cleavage and extends the half-life from about 7 minutes to roughly 2 hours, enabling once-daily dosing.
Will teduglutide cure short bowel syndrome?
No. It can dramatically reduce the need for parenteral nutrition, and a minority of patients achieve complete enteral autonomy, but stopping the drug typically reverses the gains within weeks.
How is teduglutide different from GLP-1 drugs like Ozempic?
GLP-1 agonists target metabolic and appetite pathways system-wide. Teduglutide acts specifically on the gut wall to expand absorptive surface. Same gene family, very different therapeutic effects.
Why does it cost so much?
Orphan drug pricing. SBS-IF affects only a few thousand patients in the U.S., and the manufacturer recovers development costs from a small population.
Are there any longer-acting alternatives coming?
Glepaglutide and apraglutide are in late-stage trials targeting weekly or twice-weekly dosing using albumin-binding chemistry similar to long-acting insulins and GLP-1 drugs.
Further Learning
- Peptide Delivery Challenges and Nanoparticles
- How GLP-1 Drugs Work: Ozempic Explained
- Semaglutide and Tirzepatide: A Mechanism Deep Dive
This article is for educational purposes and is not medical advice. Teduglutide is a specialized therapy with significant risks including potential acceleration of neoplastic growth. Always consult your physician before starting, changing, or stopping treatment.
